Hosted on MSN7mon
Developing new methods for targeted protein degradation
Most of these outcomes are mediated by two E3 ligases: CRBN and VHL. To fully realize the therapeutic potential of TPD, Zhang and his collaborators sought to identify additional E3 ligases to ...
BioWorld28d
Merck Sharp & Dohme prepares new KRAS G12D degrader PROTACs
Merck Sharp & Dohme LLC patents report the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase (Von Hippel-Lindau disease tumor suppressor [VHL] ligands) ...